Repare Therapeutics Inc.
RPTXDrugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
RP-3500 (camonsertib)
Advanced Solid Tumor
RP-6306
Advanced Cancer
RP-3500
Solid Tumor
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
RP-3500 (camonsertib) | Phase 2 | Advanced Solid Tumor | - | - |
RP-6306 | Phase 2 | Advanced Cancer | - | - |
RP-3500 | Phase 2 | Solid Tumor | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Repare Therapeutics Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Repare Therapeutics Inc.'s (RPTX) pipeline across Phase 2. Its lead program is RP-3500 (camonsertib) (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Repare Therapeutics Inc.'s next FDA catalyst?→
Repare Therapeutics Inc.'s (RPTX) next tracked catalyst is a Phase 2 expected September 30, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track RPTX biotech catalysts?→
Add RPTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Repare Therapeutics Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.